Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Chairman Stanley T. Crooke sold 16,500 shares of the business’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $52.45, for a total value of $865,425.00. Following the completion of the transaction, the chairman now directly owns 53,014 shares of the company’s stock, valued at approximately $2,780,584.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Ionis Pharmaceuticals, Inc. (IONS) opened at 53.94 on Wednesday. The firm’s market capitalization is $6.69 billion. The stock’s 50 day moving average price is $51.34 and its 200-day moving average price is $46.31. Ionis Pharmaceuticals, Inc. has a 12 month low of $24.58 and a 12 month high of $57.00.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Tuesday, May 9th. The company reported $0.03 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.13. Ionis Pharmaceuticals had a negative return on equity of 14.61% and a negative net margin of 4.80%. The company had revenue of $110.30 million for the quarter, compared to analyst estimates of $86.03 million. During the same period in the previous year, the company posted ($0.52) earnings per share. The firm’s revenue was up 199.2% on a year-over-year basis. Equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post ($0.27) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://stocknewstimes.com/2017/07/19/ionis-pharmaceuticals-inc-ions-chairman-stanley-t-crooke-sells-16500-shares-of-stock.html.
A number of research analysts recently commented on IONS shares. BMO Capital Markets reaffirmed a “buy” rating and issued a $59.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, June 2nd. Vetr cut Ionis Pharmaceuticals from a “hold” rating to a “sell” rating and set a $37.67 target price on the stock. in a research report on Monday, April 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 target price on shares of Ionis Pharmaceuticals in a research report on Wednesday, May 17th. Leerink Swann reiterated an “outperform” rating and issued a $45.00 target price (down previously from $47.00) on shares of Ionis Pharmaceuticals in a research report on Wednesday, May 17th. Finally, Piper Jaffray Companies set a $51.00 target price on Ionis Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 10th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $44.55.
Several large investors have recently added to or reduced their stakes in the stock. Hanseatic Management Services Inc. purchased a new stake in Ionis Pharmaceuticals during the first quarter valued at $138,000. Westpac Banking Corp purchased a new stake in Ionis Pharmaceuticals during the first quarter valued at $171,000. Capstone Asset Management Co. boosted its position in shares of Ionis Pharmaceuticals by 10.3% in the first quarter. Capstone Asset Management Co. now owns 5,148 shares of the company’s stock worth $207,000 after buying an additional 480 shares during the last quarter. World Asset Management Inc boosted its position in shares of Ionis Pharmaceuticals by 27.3% in the first quarter. World Asset Management Inc now owns 5,427 shares of the company’s stock worth $218,000 after buying an additional 1,163 shares during the last quarter. Finally, Raymond James Trust N.A. boosted its position in shares of Ionis Pharmaceuticals by 2.9% in the first quarter. Raymond James Trust N.A. now owns 5,705 shares of the company’s stock worth $229,000 after buying an additional 159 shares during the last quarter. Institutional investors own 88.72% of the company’s stock.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
